Literature DB >> 8961899

Molecular therapeutics. Methotrexate and its mechanism of action.

B N Cronstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8961899     DOI： 10.1002/art.1780391203

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  34 in total

1.  Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

Authors:  Yoshitaka Ueno; Shinji Tanaka; Masaru Shimamoto; Yoshihiro Miyanaka; Toru Hiyama; Masanori Ito; Yasuhiko Kitadai; Masaharu Yoshihara; Masaharu Sumii; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

2.  Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression.

Authors:  M F Neurath; K Hildner; C Becker; J F Schlaak; K Barbulescu; T Germann; E Schmitt; P Schirmacher; S Haralambous; M Pasparakis; K H Meyer Zum Büschenfelde; G Kollias; E Märker-Hermann
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery.

Authors:  Martin Fuerst; Henrike Möhl; Kerstin Baumgärtel; Wolfgang Rüther
Journal:  Rheumatol Int       Date:  2006-05-31       Impact factor: 2.631

4.  Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis.

Authors:  K Hildner; S Finotto; C Becker; J Schlaak; P Schirmacher; P R Galle; E Märker-Hermann; M F Neurath
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

5.  Methotrexate-Induced Epithelial-Mesenchymal Transition in the Alveolar Epithelial Cell Line A549.

Authors:  Masashi Kawami; Rika Harabayashi; Mioka Miyamoto; Risako Harada; Ryoko Yumoto; Mikihisa Takano
Journal:  Lung       Date:  2016-09-07       Impact factor: 2.584

6.  Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

Authors:  Lazaro E Aira; Patricia Hernández; Dinorah Prada; Araceli Chico; Jorge A Gómez; Zuyén González; Karla Fuentes; Carmen Viada; Zaima Mazorra
Journal:  MAbs       Date:  2015-10-15       Impact factor: 5.857

7.  When should we use parenteral methotrexate?

Authors:  Hayley Mainman; Emma McClaren; Carol Heycock; Vadivelu Saravanan; Jennifer Hamilton; Clive Kelly
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

8.  Methotrexate-mediated inhibition of nuclear factor κB activation by distinct pathways in T cells and fibroblast-like synoviocytes.

Authors:  Charles F Spurlock; Henry M Gass; Carson J Bryant; Benjamin C Wells; Nancy J Olsen; Thomas M Aune
Journal:  Rheumatology (Oxford)       Date:  2014-08-12       Impact factor: 7.580

Review 9.  Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection.

Authors:  C G Jackson; H J Williams
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 10.  Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?

Authors:  Alexandros Drosos
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.